Core Insights - Revvity (RVTY) reported revenue of $664.76 million for the quarter ended March 2025, reflecting a 2.3% increase year-over-year and a surprise of +0.39% over the Zacks Consensus Estimate of $662.17 million [1] - The company's EPS for the quarter was $1.01, up from $0.98 in the same quarter last year, resulting in an EPS surprise of +5.21% compared to the consensus estimate of $0.96 [1] Revenue and Earnings Performance - Organic revenue growth in Life Sciences was 2%, below the average estimate of 6.1% from three analysts [4] - Total organic revenue growth was reported at 4%, exceeding the average estimate of 3.6% from three analysts [4] - Organic revenue growth in Diagnostics was 5%, significantly higher than the average estimate of 1.5% from three analysts [4] Sales Metrics - Net Sales in Life Sciences reached $340.40 million, slightly above the average estimate of $338.13 million from three analysts, with a year-over-year change of +12.3% [4] - Net Sales in Diagnostics were reported at $324.37 million, slightly below the average estimate of $324.78 million from three analysts, representing a year-over-year decline of -6.6% [4] Stock Performance - Revvity's shares have returned -10.7% over the past month, compared to a -4.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Financial Performance - Washington Trust Bancorp reported revenue of $59.07 million for the quarter ended March 2025, representing a 21% increase year-over-year [1] - The earnings per share (EPS) for the quarter was $0.61, a slight decrease from $0.64 in the same quarter last year [1] - The reported revenue exceeded the Zacks Consensus Estimate of $52.98 million by 11.50%, while the EPS fell short of the consensus estimate of $0.62 by 1.61% [1] Key Metrics - The net interest margin was reported at 2.3%, matching the average estimate from two analysts [4] - The efficiency ratio was 71.4%, higher than the estimated 69.5% by two analysts [4] - Total noninterest income was $22.64 million, significantly above the estimated $16.28 million [4] - Net interest income was reported at $36.42 million, slightly below the average estimate of $36.69 million [4] Stock Performance - Over the past month, shares of Washington Trust have returned -13.1%, compared to a -5.6% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]